Search the Community

As the president of the Michigan Medical Marijuana Association, I testified before the Michigan Medical Marihuana Review Panel earlier today in support of the 21 petitions submitted by our patient and caregiver educational non-profit organization as well as other researchers, patients and caregivers, physicians and parents who combined resources to work on the petitions. There is another meeting for the panel to vote on these conditions NEXT WEEK Friday, May 4th ,2018 at the same location. I do not think there will be additional comments, but by being present you may sway the panel members. http://www.mlive.com/news/index.ssf/2018/04/michigan_considers_authorizing.html

On Friday May 4, 2018 a review panel recommended 10 new conditions to be added to the list of ailments for approval for use of medical marijuana in Michigan. Obsessive compulsive disorder Arthritis Rheumatoid arthritis Spinal cord injury Inflammatory bowel disease Ulcerative colitis Parkinson’s Tourette Syndrome Autism Chronic pain A Michigan regulator (Shelly Edgerton) who is The Department of Licensing and Regulatory Affairs Director has until July 10, 2018 to make a decision on nine of the recommendations and until Aug. 6 to make a decision on another. Only post-traumatic stress disorder has been added since 2008.

PART 1 Video of the public meeting of the Review Panel on May 4, 2018 for new qualifying conditions for medical marijuana use (part 1) See Part 2

Michigan Medical Marihuana Licensing Board Meeting 4-19-2018

The public hearing for public comments will be heard on April 27, 2018. Read more about it at http://komornlaw.com/petitions After the MMMA was enacted by a vote of 63% of Michigan voters in 2008, the legislature has declined to add any new qualifying conditions to protect patients from arrest. Senator Rick Jones even attempted to remove Glaucoma from the MMMP's list of qualifying conditions. Patients , caregivers and other interested parties wrote in opposition to the bill. A handful of petitions have been submitted over the years. LARA (and the previous MDCH department) have used various reasons and tricks to deny these petitions. Only Post Traumatic Stress Disorder has been added as a qualifying condition to the Michigan Medical Marihuana Act. Autism and Parkinson's disorder petitions were approved by the Michigan medical marihuana review board (the board consists mostly of physicians). These petitions were denied by the LARA director. The petitions were not deficient in any way and should have been accepted by LARA. We resubmitted the Autism petition again, with 20 additional research studies. Now, with the help of numerous patients, researchers, Dwight Z. and Dr. Christian Bogner along with the Michigan Medical Marijuana Association and Michael Komorn, we have assembled a massive amount of peer-reviewed medical research and government data to show that these conditions should be approved to protect patients, caregivers and physicians from arrest for the medical use of marijuana to treat their conditions. This project took months of work. Reading, organizing, searching and collecting thousands of pages of research from all over the world. Including the most up to date medical studies, peer-reviewed patient surveys and the national reviews of all medical marijuana studies by the National Academies of Science. The oldest peer-reviewed medical research paper cited within these petitions was from the first volume of The Lancet in 1889. Birch EA. The use of Indian hemp in the treatment of chronic chloral and chronic opium poisoning. The Lancet. 1889;133:625. Cannabis, Indian Hemp, Marijuana, whatever you call it, physicians were using this non-toxic plant in 1889 to treat chronic opium poisoning and opium addiction. As opioid based prescriptions are addicting and killing approximately 142 Americans each day in 2017, medical marijuana is a non-lethal non-toxic way to avoid "America enduring a death toll equal to September 11th every three weeks." The qualifying condition petitions were based primarily on the following: Already approved qualifying conditions in other medical marijuana states. Historical and ancient medical books. Patient self-reports and surveys. US Government Department of Health and Human Services Patent on using marijuana to treat many diseases and injuries, including brain injury on humans. Institute of Medicine 1999 report on medical marijuana. This report was the basis for the MMMA, specifically cited within the Michigan law, MCL 333.26422 (b). National Academies of Science (formerly the Institute of Medicine) 2017 updated report on medical marijuana. Included research not only supports each qualifying condition petition, but also answers questions that the LARA directors, physicians and medical marijuana review panel board members had asked of past petitioners. Reports on dosages, safety profiles of marijuana, statistics from the CDC and Poison Control, and information from NIH, FDA and the DEA are presented in the petitions. This information was included in order to compare the safety, effects and side-effects of medical marijuana with FDA approved prescription medications. All of the patients, caregivers, researchers, the Michigan Medical Marijuana Association and it's president Michael Komorn fully agree that marijuana should be removed from the Controlled Substances Act. Marijuana should continue to be studied as a treatment for every human and animal disease. Marijuana also should be submitted to the FDA for approval as a medicine. We fully support all clinical trials related to using marijuana as a treatment for any condition, disease or injury. As all of the scientific peer-reviewed published clinical trials show, marijuana is an effective medicine. The http://www.nih.gov website was heavily utilized throughout this project for locating scientific peer-reviewed published research, reports and information. The petitions are grouped by similar conditions, symptoms or mechanisms of treatment. Included in this post are some choice quotes from a few studies in each group of petitions. 001.-Anxiety.pdf 004.-depression.pdf 007.-Obsessive-compulsive-disorder.pdf 008.-panic-attacks.pdf 011.-Schizophrenia.pdf 012.-Social-Anxiety-Disorder.pdf Marijuana and Medicine Assessing the Science Base 1999 report from the Institute of Medicine https://directorsblog.nih.gov/2014/04/10/anxiety-reduction-exploring-the-role-of-cannabinoid-receptors/ Medical Cannabis in Arizona: Patient Characteristics, Perceptions, and Impressions of Medical Cannabis Legalization. 014.-arthritis.pdf 023.-Rheumatoid-Arthritis.pdf Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) inthe treatment of pain caused by rheumatoid arthritis Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis 025.-brain-injury.pdf 030.-Treatment-of-spinal-cord-injury.pdf 031.-asthma.pdf Effects of smoked marijuana in experimentally induced asthma. Effects of cannabis on lung function: a population-based cohort study Newspaper ad from 1876 selling marijuana cigarettes for treating asthma. You may laugh at a marijuana cigarette as a real medical treatment, but marijuana is a verified bronchodilator similar in strength to albuterol, the standard asthma medication. The medical efficacy of this specific brand of Asthma cigarettes were specifically exempted within the Single Convention on Narcotic Drugs as created by the United Nations. This means these marijuana cigarettes were still able to be sold after each country banned marijuana. https://www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1951-01-01_4_page002.html https://www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1962-01-01_4_page005.html 036.-diabetes.pdf The Health Effects of Cannabis and Cannabinoids The Current State of Evidence and Recommendations for Research (2017) The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults 044.-colitis.pdf 050.-gastric-ulcer.pdf 055.-Inflammatory-bowel-disease-IBD.pdf 064.-Ulcerative-colitis.pdf Marijuana Use Patterns Among Patients with Inflammatory Bowel Disease Minnesota Medical Cannabis Program: Patient Experiences from the First Program Year by the MN Department of Health 2016. Cannabinoids and the Urinary Bladder Cannabinoids and gastrointestinal motility: Animal and human studies Medical cannabis – the Canadian perspective Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. 106.-organ-transplant.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541500/ Medical Marijuana and Organ Transplantation: Drug of Abuse, or Medical Necessity? 107.-Non-severe-and-non-chronic-Pain.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998228/ LARA statistics show the majority of the 250,000+ patients in the MMMA are using cannabis to treat chronic pain. As we know that the medical use of marijuana can treat “severe and chronic pain” already, it can and should be used to treat regular generic pain that is not severe and chronic. The reports and information from the Minnesota Department of Health on its medical marijuana program are very detailed and informative about patients experiences with medical marijuana. Minnesota Medical Cannabis Program: Patient Experiences from the First Program Year by the MN Department of Health 2016. http://www.health.state.mn.us/topics/cannabis/about/appendixa.pdf 108.-Parkinsons.pdf Other states already approve of medical marijuana for Parkinson's Disease. Including: Georgia, Vermont, Connecticut, Florida, Illinois, Massachusetts, New Hampshire, Ohio, New Mexico, New York, Pennsylvania, West Virginia and California http://www.google.com/patents/US6630507 111.-Tourette's-Syndromequalifying.pdf Tourette’s Syndrome is an approved medical marijuana qualifying condition in Arkansas, Illinois, Minnesota and Ohio. While the MMMA covers persistant and severe Muscle Spasms, Tourette's Syndrome sufferers may not have the severe symptoms that qualify. The 1999 Institute of Medicine report states that marijuana can be used to treat Tourettes Syndrome. 112.-MMRP-Autism-Petition-2qualifying.pdf Pennsylvania Medical Marijuana Program lists Autism as a qualifying condition. There are two clinical trials for Autism and cannabis in 2017: Cannabinoids for Behavioral Problems in Autism Spectrum Disorder: A Double Blind, Randomized, Placebo-controlled Trial With Crossover. Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) https://nccih.nih.gov/health/autism https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473390/ Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study. An Open Label Study of the Use of Dronabinol (Marinol) in the Management of Treatment-Resistant Self-Injurious Behavior in 10 Retarded Adolescent Patients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648553/ DOWNLOAD ALL PETITIONS ONLY (34MB) DOWNLOAD ALL PETITIONS AND SUPPORTING STUDIES HERE (1.7GB)

Michigan Medical Marihuana Licensing Board Meeting 4-19-2018

After the MMMA was enacted by a vote of 63% of Michigan voters in 2008, the legislature has declined to add any new qualifying conditions to protect patients from arrest. Senator Rick Jones even attempted to remove Glaucoma from the MMMP's list of qualifying conditions. Patients , caregivers and other interested parties wrote in opposition to the bill. A handful of petitions have been submitted over the years. LARA (and the previous MDCH department) have used various reasons and tricks to deny these petitions. Only Post Traumatic Stress Disorder has been added as a qualifying condition to the Michigan Medical Marihuana Act. Autism and Parkinson's disorder petitions were approved by the Michigan medical marihuana review board (the board consists mostly of physicians). These petitions were denied by the LARA director. The petitions were not deficient in any way and should have been accepted by LARA. We resubmitted the Autism petition again, with 20 additional research studies. Now, with the help of numerous patients, researchers, Dwight Z. and Dr. Christian Bogner along with the Michigan Medical Marijuana Association and Michael Komorn, we have assembled a massive amount of peer-reviewed medical research and government data to show that these conditions should be approved to protect patients, caregivers and physicians from arrest for the medical use of marijuana to treat their conditions. This project took months of work. Reading, organizing, searching and collecting thousands of pages of research from all over the world. Including the most up to date medical studies, peer-reviewed patient surveys and the national reviews of all medical marijuana studies by the National Academies of Science. The oldest peer-reviewed medical research paper cited within these petitions was from the first volume of The Lancet in 1889. Birch EA. The use of Indian hemp in the treatment of chronic chloral and chronic opium poisoning. The Lancet. 1889;133:625. Cannabis, Indian Hemp, Marijuana, whatever you call it, physicians were using this non-toxic plant in 1889 to treat chronic opium poisoning and opium addiction. As opioid based prescriptions are addicting and killing approximately 142 Americans each day in 2017, medical marijuana is a non-lethal non-toxic way to avoid "America enduring a death toll equal to September 11th every three weeks." The qualifying condition petitions were based primarily on the following: Already approved qualifying conditions in other medical marijuana states. Historical and ancient medical books. Patient self-reports and surveys. US Government Department of Health and Human Services Patent on using marijuana to treat many diseases and injuries, including brain injury on humans. Institute of Medicine 1999 report on medical marijuana. This report was the basis for the MMMA, specifically cited within the Michigan law, MCL 333.26422 (b). National Academies of Science (formerly the Institute of Medicine) 2017 updated report on medical marijuana. Included research not only supports each qualifying condition petition, but also answers questions that the LARA directors, physicians and medical marijuana review panel board members had asked of past petitioners. Reports on dosages, safety profiles of marijuana, statistics from the CDC and Poison Control, and information from NIH, FDA and the DEA are presented in the petitions. This information was included in order to compare the safety, effects and side-effects of medical marijuana with FDA approved prescription medications. All of the patients, caregivers, researchers, the Michigan Medical Marijuana Association and it's president Michael Komorn fully agree that marijuana should be removed from the Controlled Substances Act. Marijuana should continue to be studied as a treatment for every human and animal disease. Marijuana also should be submitted to the FDA for approval as a medicine. We fully support all clinical trials related to using marijuana as a treatment for any condition, disease or injury. As all of the scientific peer-reviewed published clinical trials show, marijuana is an effective medicine. The http://www.nih.gov website was heavily utilized throughout this project for locating scientific peer-reviewed published research, reports and information. The petitions are grouped by similar conditions, symptoms or mechanisms of treatment. Included in this post are some choice quotes from a few studies in each group of petitions. 001.-Anxiety.pdf 004.-depression.pdf 007.-Obsessive-compulsive-disorder.pdf 008.-panic-attacks.pdf 011.-Schizophrenia.pdf 012.-Social-Anxiety-Disorder.pdf Marijuana and Medicine Assessing the Science Base 1999 report from the Institute of Medicine https://directorsblog.nih.gov/2014/04/10/anxiety-reduction-exploring-the-role-of-cannabinoid-receptors/ Medical Cannabis in Arizona: Patient Characteristics, Perceptions, and Impressions of Medical Cannabis Legalization. 014.-arthritis.pdf 023.-Rheumatoid-Arthritis.pdf Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) inthe treatment of pain caused by rheumatoid arthritis Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis 025.-brain-injury.pdf 030.-Treatment-of-spinal-cord-injury.pdf 031.-asthma.pdf Effects of smoked marijuana in experimentally induced asthma. Effects of cannabis on lung function: a population-based cohort study Newspaper ad from 1876 selling marijuana cigarettes for treating asthma. You may laugh at a marijuana cigarette as a real medical treatment, but marijuana is a verified bronchodilator similar in strength to albuterol, the standard asthma medication. The medical efficacy of this specific brand of Asthma cigarettes were specifically exempted within the Single Convention on Narcotic Drugs as created by the United Nations. This means these marijuana cigarettes were still able to be sold after each country banned marijuana. https://www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1951-01-01_4_page002.html https://www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1962-01-01_4_page005.html 036.-diabetes.pdf The Health Effects of Cannabis and Cannabinoids The Current State of Evidence and Recommendations for Research (2017) The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults 044.-colitis.pdf 050.-gastric-ulcer.pdf 055.-Inflammatory-bowel-disease-IBD.pdf 064.-Ulcerative-colitis.pdf Marijuana Use Patterns Among Patients with Inflammatory Bowel Disease Minnesota Medical Cannabis Program: Patient Experiences from the First Program Year by the MN Department of Health 2016. Cannabinoids and the Urinary Bladder Cannabinoids and gastrointestinal motility: Animal and human studies Medical cannabis – the Canadian perspective Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. 106.-organ-transplant.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541500/ Medical Marijuana and Organ Transplantation: Drug of Abuse, or Medical Necessity? 107.-Non-severe-and-non-chronic-Pain.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998228/ LARA statistics show the majority of the 250,000+ patients in the MMMA are using cannabis to treat chronic pain. As we know that the medical use of marijuana can treat “severe and chronic pain” already, it can and should be used to treat regular generic pain that is not severe and chronic. The reports and information from the Minnesota Department of Health on its medical marijuana program are very detailed and informative about patients experiences with medical marijuana. Minnesota Medical Cannabis Program: Patient Experiences from the First Program Year by the MN Department of Health 2016. http://www.health.state.mn.us/topics/cannabis/about/appendixa.pdf 108.-Parkinsons.pdf Other states already approve of medical marijuana for Parkinson's Disease. Including: Georgia, Vermont, Connecticut, Florida, Illinois, Massachusetts, New Hampshire, Ohio, New Mexico, New York, Pennsylvania, West Virginia and California http://www.google.com/patents/US6630507 111.-Tourette's-Syndromequalifying.pdf Tourette’s Syndrome is an approved medical marijuana qualifying condition in Arkansas, Illinois, Minnesota and Ohio. While the MMMA covers persistant and severe Muscle Spasms, Tourette's Syndrome sufferers may not have the severe symptoms that qualify. The 1999 Institute of Medicine report states that marijuana can be used to treat Tourettes Syndrome. 112.-MMRP-Autism-Petition-2qualifying.pdf Pennsylvania Medical Marijuana Program lists Autism as a qualifying condition. There are two clinical trials for Autism and cannabis in 2017: Cannabinoids for Behavioral Problems in Autism Spectrum Disorder: A Double Blind, Randomized, Placebo-controlled Trial With Crossover. Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) https://nccih.nih.gov/health/autism https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473390/ Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study. An Open Label Study of the Use of Dronabinol (Marinol) in the Management of Treatment-Resistant Self-Injurious Behavior in 10 Retarded Adolescent Patients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648553/ DOWNLOAD ALL PETITIONS ONLY (34MB) DOWNLOAD ALL PETITIONS AND SUPPORTING STUDIES HERE (1.7GB)

Hey guys! Sorry if this is in the wrong area but I’m a bit worried... LARA received my application and money order on Feb. 17, and it still hasn’t been cashed as of today (the 24th.) Is this unusual? Everything I’ve read says they want to cash it ASAP and usually do within 2-4 days of receiving. Anyone know what’s up? Thanks!

Effective Monday, February 26, 2018. the Bureau of Medical Marihuana Regulation will begin operating at its new location at2407 North Grand River, Lansing, Michigan. Applications for a state operating license for a marihuana facility will no longer be accepted at 611 West Ottawa Street. Those applications and payments for application fees and regulatory assessments will be accepted at the new location between the hours of 8 a.m. and 5 p.m., Monday through Friday. To allow time for processing, please arrive no later than 4:30 p.m. Applications for the medical marihuana program will not be accepted on-site. Individuals should follow the instructions provided on the application for registry identification card and mail the completed form, required supporting documentation, and fee (if applicable) to the address provided on the form. LARA is an equal opportunity employer/program. Auxiliary aids, services and other reasonable accommodations are available upon request to individuals with disabilities. For more information about LARA, please visit www.michigan.gov/medicalmarihuana Follow us on Twitter www.twitter.com/michiganLARA “Like” us on Facebook or find us on YouTube www.youtube.com/michiganLARA

Next Friday, July 31 is a very important day for the Michigan Medical Marijuana community. The MMMA, along with physicians, lawyers, and families have worked tirelessly for more than a year to add autism as a qualifying condition under the Act, and next Friday is the vote to add or deny autism into the law. Please attend this vote, particularly if you treat your child with marijuana, to show solidarity with the parents of autistic children and family members that have led this drive. Komorn Law has pledged to compensate food and gas for all families with children that attend. Just attending the panel meeting can make a huge difference, there are many people with a debilitating condition who cannot make it. If you know someone in Lansing, ask them to attend. Friday is the ideal day to show respectful support that will have a real, meaningful impact on the panel's vote, and on the futures of these parents and children in need. I am sure all of you can understand how important this vote is for the families who have children afflicted with autism. I personally would like to believe that with all the hoopla and attention towards legalization lately the patients and families of patients are not lost or overlooked. Medical cannabis is the real deal. For the last 6 years we have all shared together in the miracles of this plant. We have danced on this forum together making history in Michigan as we implement the 2008 voter initiative. The battle continues and the fight is scheduled for July 31. Your appearance will be a strong showing of unity of our medical cannabis community. It will help provide evidence that medical cannabis is real, and safe access for those afflicted with autistism must be the next step for the MMMA.

A recent radio show on NPR featured an interview with Michael Komorn a leading medical marijuana attorney in Southfield and the president of the Michigan Medical Marijuana Association In 2008, Michigan voters said yes to medical marijuana. There are reports that since 2011 it seems as if fewer patients have been signing up for medical marijuana cards. A 2013 Michigan Supreme Court ruling, patients remain protected as consumers even though sellers no longer have a clear-cut legal protection to sell. According to Komorn, there are several reasons this decline has occurred most likely due to the way the medical marijuana law was amended. Patients now register once every two years, where in the past they registered once a year. “So I think inherently the numbers are down because of that change in the law,” Komorn said. Enforcement of the law “varies from community to community, county to county,” said Komorn. “Different law enforcement agencies or even prosecutors have taken a different approach to it. Some are very hands-on and are leading the charge in terms of prosecuting and creating new cases. Others have taken a more hands-off approach, so you have a great disparity throughout the state, which is a problem.” Komorn said those differences in interpretation and enforcement mean confusion for patients and caregivers Would you like to know more? Read More…Fewer Michigan medical marijuana patients signing up Listen to the interview… http://komornlaw.com/wp-content/uploads/2015/03/20150305_SS_Komorn_MedicalMarijuana.mp3

My thoughts on the recent charges against a medical marijuana-recommending doctor in Michigan, featured on the The Huffington Post Detroit's page. http://www.huffingto..._b_1914157.html Recently, the Michigan Attorney General's office filed a formal complaint with the Licensing and Regulation Division (LARA), alleging that a physician failed to require patients to produce medical records and "failed to maintain those records," prior to and after recommending patients for medical marijuana. The first question raised is, will the Attorney General's investigation extend to all doctors, or is this only an issue because it involves medical marijuana? Through the four-year history of the Michigan Medical Marihuana Act (MMMA), the physician certification process has been a hot topic, with opponents of the Act routinely criticizing this aspect of the law. To some, these doctors are helping patients find relief through medical marijuana in light of professional risk, complaints and potential criminal investigations. Opponents, however, maintain that obtaining one's medical marijuana card is too easy, citing that as of one year ago, more than 90 percent of the state's 64,000 patients were using medical marijuana to treat severe pain, muscle spasms or nausea. A year later, the state has more than 130,000 registered medical marijuana patients. One fact often overlooked is that LARA has an entire page on its website devoted to pain management, and nearly 30 percent of Michigan's residents have sought treatment for an acute pain condition in the past year. The current legislative process and proposed bills being discussed in Michigan's House and Senate are opening a potentially dangerous debate, not trusting physicians to make the right decision and injecting politics into our right to privacy in healthcare. No other prescription or diagnosis is as scrutinized as a medical marijuana recommendation, despite doctors being tasked with control, regulation and administering thousands of other substances throughout their careers. If Michigan policymakers truly want to protect the medical marijuana community and ensure safe access to medicine, they need to focus on amending the Public Health Code, not the MMMA or attacking those recommending the medicine. Doing so would first allow and recognize the use of medical marijuana and protect recommending physicians, preventing physicians from shying away from medical marijuana for fear of prosecution. The issue of medical marijuana is a public health issue, not a public safety issue. In order for the MMMA to truly work as intended, and to give the voters of Michigan what they approved, the state needs to trust and rely on board-certified physicians, not politicians, to make proper decisions about the use and recommendation of medical marijuana. Michael A. Komorn Attorney and Counselor Law Office of Michael A. Komorn 3000 Town Center, Suite, 1800 Southfield, MI 48075 800-656-3557 (Toll Free) 248-351-2200 (Office) 248-357-2550 (Phone) 248-351-2211 (Fax) Email: michael@komornlaw.com Website: www.komornlaw.com Check out our Radio show: http://www.blogtalkr...lanetgreentrees CALL IN NUMBER: (347) 326-9626 Live Every Thursday 8-10:00p.m. PLANET GREENTREES w/ Attorney Michael Komorn The most relevant radio talk show for the Michigan Medical Marijuana Community. PERIOD.